Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.0971
-0.0006 (-0.59%)
At close: Nov 28, 2025
Oncotelic Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
26
Market Cap
42.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 1.74M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |
Oncotelic Therapeutics News
- 4 days ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation - GlobeNewsWire
- 8 days ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation - GlobeNewsWire
- 4 weeks ago - NetworkNewsAudio Announces Audio Press Release (APR) on Transforming Once-Marginal Drugs into Category-Changing Assets - GlobeNewsWire
- 4 weeks ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies - GlobeNewsWire
- 4 weeks ago - Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus) - GlobeNewsWire
- 4 weeks ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies - GlobeNewsWire
- 5 weeks ago - Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus) - GlobeNewsWire
- 5 weeks ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring Return of Dr. Vuong Trieu, CEO of Oncotelic Therapeutics Inc. - GlobeNewsWire